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Abstract
Background: Autosomal recessive cerebellar ataxias (ARCA) are a group of neurodegenerative disorders characterized
by early onset of gait impairment, disturbed limb coordination, dysarthria, and eye movement abnormalities, most
likely due to the degeneration of cerebellum, brainstem, and spinal cord. Despite of the rarity, ARCA are both clinically
and genetically heterogeneous. To date, more than 30 culprit genes have been identified in ARCA. Unraveling the
specific causative mutation in cases with ARCA remains challenging so far.
Methods: Three ARCA pedigrees of Chinese ancestry were recruited. Clinical features were evaluated and peripheral
blood was collected after obtaining the written inform. Laboratory examinations, brain MRI, and EMG were performed
for all the affected individuals. Genomic DNA was extracted, followed by the screening of GAA repeat expansion in FXN
gene to exclude Friedreich’s ataxia. Targeted next-generation sequencing combining Sanger sequencing was
performed in each proband of these families.
Results: Compound heterozygous mutations, c.3190G > T (p.E1064X) and c.4883C > G (p.S1628X) of senataxin (SETX)
gene were identified in one family with two affected cases. Both of the patients presented with early onset of unsteady
walk, dysarthria, and diplopia. EMG test revealed decreased conduction velocity and evoked potential of both motor
and sensory nerve. Moreover, elevated serum alpha-fetoprotein (AFP) and apparent cerebellar atrophy were observed.
These features were typical features of ataxia with oculomotor apraxia type 2 (AOA2) and in line with the genetic
results. However, no specific mutation was identified in the other two pedigrees.
Conclusions: We identified novel compound heterozygous mutations of SETX in Chinese AOA2 pedigree, which
broaden the mutation spectrum of SETX. To our knowledge, this is the first report concerning Chinese AOA2 cases
with SETX mutations.
Keywords: Autosomal recessive cerebellar ataxias, Targeted next-generation sequencing, Ataxia with oculomotor
apraxia type 2, Senataxin
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Background
Autosomal recessive cerebellar ataxias (ARCA) are a
large group of neurodegenerative disorders characterized
by autosomal recessive inheritance, cerebellar ataxia, and
early onset of disease [1]. Clinically, ARCA are associ-
ated with diverse involvement of central and peripheral
nervous systems, and with many systemic signs [2]. It
comprises many subtypes, among which Friedreich’s
ataxia (FA), ataxia telangiectasia (AT), and ataxia with
oculomotor apraxia (AOA) are the most frequent [3].
The overall prevalence of ARCA is estimated to be about
5 to 6 per 100,000 [4]. Despite the rarity of ARCA, they
are very heterogeneous in age at onset, manifestations,
disease course, and progression. To date, more than 30
causative genes have been identified in ARCA [1, 2],
which were therefore divided into many subtypes.
Although many culprit genes have been identified, no
genetic mutation or variance is detected in approxi-
mately half of the ARCA patients [5].
A simple and effective approach to detect the causative
mutations in ARCA is warranted. Sanger sequencing is a
classic and convenient method to screen genetic muta-
tions or variants [6]. However, it is laborious and time-
consuming. The high throughput whole exome or whole
genome sequencing is too expensive to be widely applied
[7]. The recently developed targeted next-generation
sequencing (NGS) has shown distinct advantage in
molecularly diagnosing inherited diseases, especially in
neurologic disorders [6]. By now, it has been applied
in inherited ataxia [8], amyotrophic lateral sclerosis
(ALS) [9], Charcot-Marie-Tooth (CMT) [10], heredi-
tary spastic paraplegia (HSP) [11], and so on. We
have successfully used this technology to diagnose
ALS and CMT [9, 10]. In this study, we collected
three well defined ARCA families and screened the
causative mutations using targeted NGS.
Methods
Subjects
Three Chinese Han pedigrees with diagnosis of ARCA
were enrolled (Fig. 1). The clinical presentations were
evaluated by at least two senior neurologists. The
laboratory tests, electromyography (EMG), and brain
magnetic resonance imaging (MRI) scanning were
carried out. Patients were assigned to an ARCA diag-
nosis if they presented cerebellar features (such as
progressive limb/trunk ataxia, nystagmus, dysarthria,
intentional tremor, and cerebellar atrophy on brain
MRI) and autosomal recessive inheritance. A diagno-
sis of ARCA was made according to the Harding
diagnostic criteria [12]. In addition, 500 healthy indi-
viduals of matched geographical ancestry were re-
cruited as controls. Written informed consent was
obtained from each participant and this study was
approved by Ethic Committee of Second Affiliated
Hospital, Zhejiang University School of Medicine.
Targeted next-generation sequencing
Genomic DNA was extracted from 3 mL peripheral
blood using QIAamp genomic DNA kits (Qiagen,
Hilden, Germany). Before targeted NGS, all the pro-
bands were screened for GAA repeat expansion in
frataxin (FXN) gene to exclude the possibility of FA [13].
Targeted capture, library preparation, and sequence
Fig. 1 Pedigrees of 3 ARCA families. Squares indicate males; circles indicate females; the black symbols indicate affected individuals; diagonal lines
across symbols indicate deceased individuals; arrows indicate the probands. Abbreviation: ARCA = autosomal recessive cerebellar ataxias
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amplification of 39 ARCA causative genes (seen in
Additional file 1: Table S1) were then performed as previ-
ously described [9]. The deep sequencing was con-
ducted on the Illumina HiSeq2000 platform (Genergy
Biotechnology CoLtd, Shanghai, China).
Sequence analysis
The sequenced reads were aligned to human reference
genome (UCSC hg 19) (http://hgdownload.cse.ucsc.edu/)
through Burrows-Wheeler Aligner [14]. We collected
reads that were situated in the targeted regions for inser-
tions, deletions and single nucleotide variants analysis.
Genome Analysis Tool kit1.6 (GATK) tools were applied
to call variants [15]. All annotation databases down-
loaded from the UCSC Genome Browser was used to
annotate the variants [16]. It is hypothesized that the
frequency of mutations causing ARCA should be low in
general population. Therefore, variants with a minor
allele frequency higher than 5 % in dbSNP database,
1000 Genomes Project, ExAc Browser, and Exome
Sequencing Project were filtered out. Benign variants
were identified and ruled out from the variant list by
SIFT software (http://sift.jcvi.org/).
Sanger sequencing
Sanger sequencing was performed on ABI 3730 DNA
Sequencer to validate the filtered variants. For co-
segregation analysis, all affected and unaffected familial
members were screened to confirm the identified vari-
ants. Moreover, 500 unaffected healthy controls were
sequenced for the detected mutations. The sequencing
results were mapped to human reference genome pub-
lished in Ensembl (http://www.ensembl.org/).
Results
Identification of variants in 39genes associated with
ARCA by targeted NGS
Targeted NGS was performed in each proband (Family
1:III-3, Family 2:II-2, Family 3:II-8) of the three ARCA
pedigrees. According to the high throughput of this
approach, an average of 98.72 % targeted regions was
covered with >50X. After single nucleotide variants,
insertions and deletions calling, an average of 180.6 vari-
ants involving coding and noncoding regions was
detected in each sample. Given that ARCA are a group
of rare disorders, it is less possible that causative variants
will be present in general population. Therefore, variants
formerly published in dbSNP database, 1000 Genomes
Project, ExAc Browser, and Exome Sequencing Project
were excluded. After the initial filtration, the candidate
variants were reduced to 7.3 per proband. The damage
variants were then prioritized by SIFT software. After
this filtering, the candidate variants were further de-
creased to 6.6 per subject (Additional file 2: Table S2).
Two novel mutations in SETX confirmed by Sanger
sequencing
As the ARCA was inherited in an autosomal recessive
manner, we were then focused on homozygous and
compound heterozygous mutations. After verification
by Sanger sequencing, we identified compound heterozy-
gous SETX mutations, c.3190G > T (p.E1064X) and
c.4883C >G (p.S1628X), in the proband (III-3) of Family
1 (Fig. 2c, d). Both of these two mutations were nonsense
mutations and located in exon 10, a relatively conserved
medium region of SETX.A further validation revealed that
the proband’s sister (III-2) carried p.S1628X and p.E1064X
mutation too, while her mother carried heterozygous
p.S1628X and her father carried heterozygous p.E1064X.
These suggested that the identified mutations co-
segregated with the disease in Family 1. In addition, these
mutations were absent in 500 matched controls. However,
no mutation was found in the other two probands.
The clinical presentations of patients carrying SETX
mutations
The detailed clinical characteristics of four ARCA pa-
tients were summarized in Table 1. The proband (III-3)
in Family 1 was a 23-year-old female who had 7 years of
progressive gait difficulty. She had normal delivery and
postnatal period. Her developmental milestones were
unremarkable until the age of 16, when she exhibited
unstable gait and slightly slurred speech. She felt like
walking on cotton and fell to the ground sometime.
EMG was not performed at that time. Two years after
the onset, she recognized that her speech disturbance
was worsened and she could not write neatly and use
chopsticks stably. In the following one year, she pre-
sented with dysarthria and double vision. She noticed
that her stagger was aggravated in the dark. She also
complained that she often forgot the trifle things of life.
Her swallowing was essentially normal with rare bucking
after drinking. When she sought her medical attention
in our hospital at age of 22, she exhibited severe gait un-
steadiness, dysarthria, and slurred speech. Neurological
examinations revealed horizontal nystagmus but normal
ocular movements. No amyotrophy of muscle was no-
ticed. The muscle strength and tension were normal.
There was no abnormity of sense in her limbs and trunk.
The deep tendon reflexes were decreased in her lower
limbs, and Babinski’s sign was bilaterally positive.
Finger-nose test and heel-knee-shin test were abnormal.
Romberg’s sign was positive. Mini Mental State Examin-
ation (MMSE) revealed a score of 29/30, suggesting that
her recognition was not impaired. Laboratory findings
revealed normal albumin, ferritin, Vitamin B12, cerulo-
plasmin, cholesterol, and IgG. However, her serum a-
fetoprotein (AFP) was elevated (40.3, normal <20 ng/ml)
and the serum level of low density lipoprotein (LDL)
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was reduced (1.79, normal 2.1 ~ 3.1nmol/L). Lumbar
puncture revealed uninformative findings. EMG test
revealed decreased conduction velocity and evoked po-
tential of both motor and sensory nerve. Brain MRI
demonstrated atrophy of cerebellar predominantly in
vermis and hemispheres (Fig. 2a, b).
The proband’s 25-year-old sister (III-2) had similar
symptoms to her. At the age of 20, she began to feel diz-
ziness and noticed gait difficulty. One year later, her
walk unsteadiness was worsened, especially in the dark.
In the following half one year, she gradually exhibited
slurred speech and diplopia. Swallowing was not im-
paired. Two years after the onset, she developed tremor
of both hands. When she was admitted in our hospital,
she presented with noticeable ataxia, poem-like lan-
guage, and intention tremor. She could not walk without
the help of others. On cranial nerve examinations, she
showed horizontal and vertical nystagmus in both eyes.
Noticeable amyotrophy was observed in her lower limbs.
However, the muscle strength, tension, and sense were
basically normal. Deep tendon reflexes were disappeared
in lower limbs and decreased in the upper limbs. Right
Babinski’s sign was positive. Finger-nose test and heel-
knee-shin test were clumsy, with decomposition and
dysmetria on both sides. MMSE test was unremarkable,
with a score of 28/30. Blood inspections revealed an in-
crease of serum AFP (81.8, normal <20 ng/ml) and a
decreased LDL (1.68, normal 2.1 ~ 3.1nmol/L). Other
laboratory results were uninformative and cerebrospinal
fluid examinations were normal. EMG test revealed
reduced conduction velocity and evoked potential of
motor nerve. The velocity of bilateral sural nerve and
peroneus superficial nerve could not be detected. The
evoked potential of sense nerves was decreased. Brain
MRI showed apparent cerebellar atrophy.
The proband’s brother (III-1) was 28 years old at
present. He did not complain about any gait problem,
slurred speech, or diplopia. His serum AFP was within
Fig. 2 Brain magnetic resonance imaging of the proband III-3 (a) and the patient III-2(b) in Family 1. Left: axial T1-weighted image showing atrophy of
the cerebellar vermis. Right: mid-line sagittal T2-weighted image showing cerebellar atrophy, particularly evident in the vermis and hemispheres, with
enlargement of the fourth ventricle. Chromatogram and conservation of p.E1064X mutation (c) and p.S1628X mutation (d) within SETX. The upper
panel depicts the reference sequence. The lower panel represents heterozygous mutated sequence
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normal range. Brain MRI was unremarkable. Genetic in-
vestigations revealed a heterozygous p.E1064X mutation.
Discussion
In this study, we collected three ARCA pedigrees of
Chinese ancestry and performed targeted next-
generation sequencing in each proband of these families.
After verification by Sanger sequencing, we identified
compound heterozygous mutations (p.S1628X/p.E1064X)
within SETX in one family, in which there were two
affected cases and one healthy sibling. Both of the two
patients presented with unsteady walk, dysarthria, and
diplopia. EMG test revealed peripheral nerve damage.
Moreover, elevated serum AFP and apparent cerebellar
atrophy were observed in these two cases. Taken together,
these were in line with the features of AOA2, which was
characterized by juvenile-onset cerebellar ataxia, oculo-
motor apraxia, sensorimotor neuropathy, marked cerebel-
lar atrophy, and elevated serum AFP [17]. The prevalence
of AOA2 was low worldwide and rare in Asian ethnicity.
Of note, this disease has not been documented in Chinese
Han population so far. To our knowledge, this is the first
report of Chinese AOA2 cases.
To date, near 100 mutations within SETX have been
identified in AOA2 cases (http://www.hgmd.cf.ac.uk/).
Among these mutations, there is a maximum ratio in
exon 10 of SETX. In this study, the identified p.S1628X
and p.E1064Xmutations were also located in the exon
10. Due to premature of stop codon, these two nonsense
mutations brought about the loss of senataxin’s essential
role in DNA repair and RNA processing [18]. In
addition, these two mutation were predicted to be
disease causing by the SIFT. Although we did not per-
form functional experiments in this study, these two
mutations were regarded as pathogenic mutations for
the AOA2 in this family, according to the American
College of Medical Genetics and Genomics (ACMG)
standards and guidelines [19]. However, further functional
investigations were required to elucidate the pathogenicity
of the identified novel mutations in the future.
Oculomotor apraxia is a specific feature of AOA2, but
not all the AOA2 cases exhibited abnormal ocular move-
ments. Approximately half of AOA2 cases were reported
to have oculomotor apraxia [17, 20, 21]. In this study,
both the cases in Family 1 had diplopia, but their ocular
movements were basically normal. This suggested that
oculomotor apraxia might not be the essential factor for
the diagnosis of AOA2. Alternatively, the cases have not
developed oculomotor apraxia yet because of the early
stage of the disease. A subsequent follow-up is required
in the future. In addition, the phenotype of these two
cases was not identical, albeit they carried the same
SETX mutations. The older sister (III-2) had a later
onset of ataxia but a more severe disability than that in
the proband (III-3). She tended to have a more rapid
progression. Since the sister had higher serum AFP, we
speculated that AFP might have important effect on the
pathogenesis of AOA2. Certainly, further research about
the role of elevated serum AFP in neurologic diseases is
warranted in large sample. Additionally, the disease
course and prognosis of these two cases need further
follow up.
Due to the rarity of AOA2, accurate diagnosis at early
stage of the disease remains challenging in clinical prac-
tice. For these cases with early onset of ataxia, oculo-
motor impairment, and recessive history, it is necessary
to inspect serum AFP and make EMG test. If the serum
AFP is elevated, a diagnosis of AT or AOA2 should be










Gender F F F F
Age at onset
(years)
20 16 30 25
Disease duration
(years)
5 7 20 19
Initial
symptom
GU GU/SS GU GU/SS/T
Ataxia TL L L TL
Nystagmus H V _ H
Slow saccade _ + _ _
Diplopia + + _ _
Dysarthria + + + +
Tremor TL L _ TL
Pes cavus + + _ _








81.1 40.3 9.74 NA
LDL (2.1 ~ 3.1 ng/mL) 1.68 1.79 4.16 NA
cholesterol
(3.1–6 nmol/L)
3.90 3.45 7.84 NA
triglyceride
(<1.69 nmol/L)
0.46 0.71 2.76 NA
MMSE (30) 28 29 NA NA
EMG SMN SMN NA NA
Brain MRI CA CA CA CA












CA cerebellar atrophy, F female, GU gait unsteadiness, H horizontal, HV
horizontal and vertical, L limbs, NA non-available, T termor, TL trunk and limbs,
SMN sensorimotor neuropathy, SS screening speech, + positive, _ negative
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considered. If EMG further reveals peripheral nerve
damage, a suspected diagnosis of AOA2 can be made
and genetic screening of SETX mutations is needed. Of
course, it is still challenging to decide which gene should
be screened solely depending on the cases’ clinical fea-
tures. On one hand, the phenotypes of ARCA were
heterogeneous. On the other hand, the manifestations of
patients were varying at different stage of the disease.
For this reason, targeted NGS enables us to capture and
sequence multiple genomic regions of interest. It is
promising that this technique may become a routine ap-
proach to molecularly diagnose inherited diseases in the
future. However, the difficulty in detecting nucleotide
repeat expansions is the limitation of this approach and
may result in the loss of some valuable information and
artificial bias for assessment.
Conclusions
In summary, we identified novel compound heterozygous
mutations in SETX by targeted next-generation sequen-
cing, which broaden the spectrum of SETX mutations. Al-
though the role of AFP in the pathogenesis of AOA2
remains unclear, it seems to be a useful biomarker in the
diagnosis of AOA2. In the other two pedigrees, we did not
identify any causative mutations. It is possible that there
may be some newly causative genes unselected in our tar-
geted panel. Alternatively, they may be caused by novel
nucleotide repeat expansions which were not detected by
routine screening. These two pedigrees need further gen-
etic investigations in the future. With the improvements
of NGS technology and the bioinformatic analysis ap-
proach, it is believed that the individuals with hereditary
neurologic disorder may eventually have a molecular diag-
nosis through NGS approach.
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